What was the primary driver of AbbVie's revenue growth in the first half of 2025?

The primary driver of AbbVie's revenue growth in the first half of 2025 was the strong performance of its immunology products, Skyrizi and Rinvoq, which experienced significant year-over-year increases in net revenues. These gains helped offset the decline in Humira sales.

How is AbbVie managing the decline in Humira sales?

AbbVie is managing the decline in Humira sales, which is attributed to biosimilar competition, by focusing on its diversified portfolio and the growth of newer products like Skyrizi and Rinvoq. The company is also investing in its pipeline to develop future growth drivers.

What are some of AbbVie's recent strategic moves in pipeline development?

AbbVie has been active in expanding its pipeline through acquisitions and licensing agreements. Notable recent activities include the proposed acquisition of Capstan Therapeutics for an in vivo targeted CAR-T therapy, the acquisition of Nimble Therapeutics for oral peptide therapeutics, and a licensing agreement with Gubra A/S to enter the obesity market.

How did contingent consideration impact AbbVie's financial results?

Changes in the fair value of contingent consideration liabilities had a significant impact on AbbVie's financial results, contributing $4.3 billion to 'Other expense, net' in the first six months of 2025. This was primarily driven by higher estimated Skyrizi sales, the passage of time, and lower discount rates.

ABBV 10-Q Quarterly Report Q2 FY2025 — Revenue, Net Income, EPS

Summary

AbbVie Inc. reported strong performance for the first half of 2025, with net revenues reaching $28.8 billion, a 7.4% increase year-over-year, driven by robust growth in its immunology portfolio, particularly Skyrizi and Rinvoq, which saw increases of 65.8% and 48.5% respectively. Despite a significant decline in Humira sales due to biosimilar competition, the company's diversified revenue streams and successful new product launches have offset this impact. Operating earnings for the period were $8.6 billion, demonstrating solid profitability. The company continues to strategically invest in its pipeline, announcing significant advancements and new licensing agreements in areas like obesity, neuroscience, and oncology. AbbVie also made considerable progress in managing its financial resources, generating $6.8 billion in operating cash flow and actively managing its debt and capital structure. The company declared a quarterly cash dividend of $1.64 per share, underscoring its commitment to returning value to shareholders.

Financial Highlights

56 data points

Beta

Revenue

$15.42B

0.7% Gross Margin

Net Income

$938.00M

0.1% Net Margin

EPS (Diluted)

$0.52

Total Assets

$137.18B

Cash & Equivalents

$6.47B

Free Cash Flow

$4.88B

Financial Statements

Beta

Revenue	$15.42B
Cost of Revenue	$4.35B
Gross Profit	$11.08B
SG&A Expenses	$3.25B
Operating Expenses	$10.53B
Operating Income	$4.89B
Interest Expense	$740.00M
Net Income	$938.00M
EPS (Basic)	$0.52
EPS (Diluted)	$0.52
Shares Outstanding (Basic)	1.77B
Shares Outstanding (Diluted)	1.77B

Key Highlights

1Total net revenues grew 7.4% to $28.8 billion for the first six months of 2025, compared to the same period in 2024.
2Skyrizi and Rinvoq demonstrated substantial growth, with net revenues increasing by 65.8% and 48.5% respectively, signaling strong market adoption.
3Humira's net revenues declined by 54.3%, reflecting the ongoing impact of biosimilar competition.
4Operating earnings reached $8.6 billion for the first six months of 2025.
5AbbVie announced significant pipeline advancements and strategic acquisitions/licensing agreements, including entry into the obesity market with the Gubra collaboration.
6Cash flow from operations was robust at $6.8 billion for the first six months of 2025.
7The company declared a quarterly cash dividend of $1.64 per share, reflecting continued commitment to shareholder returns.

AbbVie Inc. Quarterly Report for Q2 Ended Jun 30, 2025

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions